Thyroid hormone pharmacology underlies clinical decisions encountered daily across internal medicine, endocrinology, obstetrics, oncology, and critical care. Whether optimizing levothyroxine dosing in a pregnant patient, managing drug-induced hypothyroidism from immune checkpoint inhibitors, interpreting a discordant thyroid-stimulating hormone (TSH) in a severely ill patient, or selecting among targeted agents for radioiodine-refractory thyroid cancer, the clinician who commands the underlying physiology and pharmacokinetics will consistently make better therapeutic decisions. This module builds that foundation: the hypothalamic-pituitary-thyroid (HPT) axis as a regulated feedback system, the enzymatic machinery of hormone biosynthesis and peripheral activation, the nuclear receptor isoforms that determine tissue-specific responses, and the absorption, distribution, metabolism, and elimination characteristics of the principal thyroid hormone preparations, with emphasis on the clinically significant drug interactions that alter their efficacy.
The hypothalamic-pituitary-thyroid (HPT) axis operates as a classic negative-feedback endocrine loop whose components are individually targetable by drugs and disease. Thyrotropin-releasing hormone (TRH), a tripeptide secreted in a pulsatile fashion from hypophysiotropic neurons in the paraventricular nucleus of the hypothalamus, binds a G-protein-coupled receptor on pituitary thyrotroph cells, activating phospholipase C (PLC) and stimulating both synthesis and secretion of thyroid-stimulating hormone (TSH). Dopamine and somatostatin tonically inhibit TSH secretion from the thyrotroph; this explains the mild secondary hypothyroidism occasionally seen with prolonged high-dose dopamine infusion and the transient TSH suppression observed with somatostatin analogues used in acromegaly treatment.1
TSH is a 28-kDa glycoprotein composed of a non-covalently linked alpha subunit shared with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and human chorionic gonadotropin (hCG), and a hormone-specific beta subunit. The shared alpha subunit has direct clinical relevance: hCG reaches very high concentrations in the first trimester of pregnancy and in gestational trophoblastic disease, cross-reacts with the TSH receptor, and can suppress TSH while stimulating thyroid hormone secretion sufficiently to cause gestational hyperthyroidism. TSH binds a leucine-rich repeat G-protein-coupled receptor on thyroid follicular cells, coupling primarily to Gs (adenylyl cyclase/cyclic AMP) at physiological concentrations; cyclic AMP (cAMP)-mediated signaling drives iodide trapping, organification, thyroglobulin (Tg) synthesis, and ultimately thyroxine (T4) and triiodothyronine (T3) secretion.1,2
Negative feedback is mediated primarily by T3 acting on the pituitary thyrotroph and, to a lesser extent, on hypothalamic TRH neurons. The pituitary is uniquely rich in type 2 deiodinase (D2), which converts T4 to the more potent T3 locally within the thyrotroph, making TSH suppression highly sensitive to circulating T4 levels even before peripheral T3 rises. This is why TSH is the most sensitive single marker of levothyroxine adequacy: a TSH within the reference range confirms sufficient T3 signal at the pituitary, and a persistently elevated TSH on stable levothyroxine therapy almost always indicates inadequate dosing or an absorption problem rather than a defect in peripheral T3 generation.1,3
The set point of the HPT axis is individually calibrated and stable within a given person. Population-based TSH reference ranges (approximately 0.4–4.0 mIU/L) encompass variation across individuals, but each patient's euthyroid TSH tends to cluster in a narrow personal range. This intra-individual stability underlies the recommendation to titrate levothyroxine to symptom resolution and a TSH in the lower half of the reference range, and it explains why some patients remain symptomatic with a TSH that is technically within the population normal range but outside their personal set point.3
The TSH-free T4 relationship is log-linear: a twofold change in free T4 produces roughly a 100-fold change in TSH. This amplification makes TSH a highly sensitive detector of small changes in thyroid hormone status, but also means that a TSH of 8 mIU/L represents a much smaller hormone deficit than a TSH of 80 mIU/L, even though both are equally elevated. A suppressed TSH of 0.1 mIU/L carries very different clinical weight depending on whether the patient is on intentional suppressive therapy for thyroid cancer or is a post-menopausal woman on standard replacement dosing.
Thyroid hormone biosynthesis is a sequential enzymatic process that begins with iodide capture from the circulation and ends with secretion of thyroxine (T4) and triiodothyronine (T3) into the bloodstream; each enzymatic step is a target of disease or pharmacological intervention. The sodium-iodide symporter (NIS), encoded by the SLC5A5 (solute carrier family 5 member A5) gene and expressed on the basolateral membrane of thyroid follicular cells, cotransports two sodium ions with each iodide ion, concentrating iodide within the thyrocyte to levels 20–40 times that of plasma. NIS is the molecular basis for radioactive iodine (RAI) uptake, since the isotope iodine-131 (I-131) enters the thyroid by exactly the same mechanism as stable iodide. NIS expression is upregulated by thyroid-stimulating hormone (TSH) and downregulated by high iodide concentrations and perchlorate, the last of which competitively inhibits NIS and is used therapeutically in iodine-excess thyrotoxicosis.2,4
Once inside the follicular cell, iodide is transported across the apical membrane into the follicular lumen. In the lumen, thyroid peroxidase (TPO), a heme-containing enzyme anchored to the apical membrane, catalyzes two sequential reactions using hydrogen peroxide generated by DUOX2 (dual oxidase 2): organification, in which iodide is oxidized and covalently attached to tyrosyl residues on thyroglobulin (Tg), forming monoiodotyrosine (MIT) and diiodotyrosine (DIT); and coupling, in which two iodotyrosyl residues are joined oxidatively to form T4 (DIT + DIT) or T3 (DIT + MIT). Thyroglobulin is a large dimeric glycoprotein (660 kDa) serving as both the scaffold for iodination and the storage matrix for thyroid hormones within follicular colloid. Thionamide drugs, including methimazole and propylthiouracil (PTU), inhibit TPO and block both organification and coupling, which is the primary mechanism of their antithyroid action.2,4,5
Hormone secretion begins with TSH-driven endocytosis of colloid into the follicular cell, where lysosomal proteases cleave T4 and T3 from Tg. The liberated hormones are released across the basolateral membrane into capillary blood. The thyroid gland secretes approximately 80–100 mcg of T4 and 5–10 mcg of T3 daily under basal conditions; because T4 is secreted in far greater quantities, clinical effectiveness of thyroid hormone replacement depends on the fidelity of peripheral T4-to-T3 conversion by deiodinase enzymes, which accounts for approximately 80% of circulating T3 production. Excess iodide transiently inhibits organification and coupling through the Wolff-Chaikoff effect, an autoregulatory mechanism exploited clinically with Lugol's iodine solution and saturated solution of potassium iodide (SSKI) in thyroid storm and pre-surgical preparation.2,5
Acute iodide loading inhibits TPO-mediated organification within hours, transiently blocking new thyroid hormone synthesis. This effect is exploited in two situations: (1) pre-operative preparation of the hyperthyroid gland, where Lugol's solution given for 7–10 days reduces gland vascularity, making surgery safer; and (2) thyroid storm, where iodide given at least one hour after thionamide loading blocks ongoing hormone release. The thyroid escapes Wolff-Chaikoff inhibition after several days by downregulating NIS, which is why iodide alone is not a durable antithyroid therapy.
Peripheral metabolism of thyroid hormones is governed by a family of selenocysteine-containing deiodinase enzymes that remove specific iodine atoms from thyroxine (T4) and other iodothyronines, generating either the active hormone triiodothyronine (T3) or the inactive metabolite reverse T3 (rT3). All three deiodinase isoforms require selenium as a cofactor, which explains why severe selenium deficiency can impair thyroid hormone activation and produce a biochemical pattern resembling central hypothyroidism. Type 1 deiodinase (D1), encoded by DIO1 (deiodinase iodothyronine type 1 gene) and expressed primarily in the liver, kidney, thyroid, and skeletal muscle, performs 5'-deiodination of T4 to generate T3 and also clears rT3 from circulation. D1 is inhibited by propylthiouracil (PTU), amiodarone, and propranolol at high doses, which accounts for the peripheral T3-lowering effect of PTU beyond its thyroid peroxidase (TPO) inhibition and for the rise in rT3 seen with amiodarone.5,6
Type 2 deiodinase (D2), encoded by DIO2 (deiodinase iodothyronine type 2 gene) and expressed in the pituitary, brain, brown adipose tissue, heart, and skeletal muscle, exclusively performs 5'-deiodination of T4 to T3 and is the primary source of intracellular T3 in the brain and pituitary. D2 activity is rapidly downregulated when T4 concentrations rise and upregulated in hypothyroid states, serving as a local homeostatic buffer. The DIO2 gene contains a common functional polymorphism (Thr92Ala, rs225014) that reduces D2 catalytic efficiency; patients homozygous for the Ala92 variant may have impaired T4-to-T3 conversion in D2-expressing tissues including the brain, and some clinical data suggest these individuals report greater wellbeing with combination T4/T3 (levothyroxine plus liothyronine) therapy than with levothyroxine monotherapy, though this remains under active investigation.6,7
Type 3 deiodinase (D3), encoded by DIO3 (deiodinase iodothyronine type 3 gene) and expressed at high levels in the placenta, fetal brain, and fetal liver, inactivates both T4 (by inner ring 5-deiodination to rT3) and T3 (by inner ring 5-deiodination to T2). D3 serves a protective function in the fetus and placenta, preventing premature exposure of fetal tissues to physiologically active thyroid hormone during a period when fetal T3 concentrations are tightly regulated for normal neurodevelopment. In severely ill patients, widespread upregulation of D3 in peripheral tissues and simultaneous downregulation of D1 produce the sick euthyroid syndrome (also called nonthyroidal illness syndrome): low T3, elevated rT3, low or normal thyroid-stimulating hormone (TSH), and normal or slightly low T4, without primary thyroid gland dysfunction.5,6
In critically ill patients, deiodinase shifts reduce T3 and elevate rT3 as an adaptive response that reduces metabolic demand. TSH is characteristically low-normal or transiently suppressed, and free T4 may be low due to reduced binding protein synthesis and drug displacement. Levothyroxine administration in this setting has not been shown to reduce mortality in any adequately powered randomized trial and may be harmful. Treatment should be directed at the underlying illness. Thyroid function tests should be rechecked 4–6 weeks after recovery before concluding that permanent thyroid disease is present.
Thyroid hormones exert the majority of their effects through nuclear thyroid hormone receptors (TRs), members of the nuclear receptor superfamily encoded by two genes: THRA (producing TRalpha1 and TRalpha2) and THRB (producing TRbeta1 and TRbeta2). TRalpha1 and TRbeta1 are the principal transcriptionally active isoforms. TRalpha1 predominates in the heart, bone, and gastrointestinal (GI) tract, which explains why excess thyroid hormone at these sites produces tachycardia, atrial fibrillation (AF), accelerated bone resorption, and hyperdefecation, while deficiency causes bradycardia, heart failure (HF), and constipation. TRbeta1 predominates in the liver, where it regulates cholesterol metabolism, explaining the dyslipidemia of hypothyroidism, and in the cochlea, where THRB mutations cause resistance to thyroid hormone syndrome accompanied by sensorineural hearing loss.8,9
TRbeta2 is expressed almost exclusively in the pituitary thyrotroph and hypothalamic thyrotropin-releasing hormone (TRH) neurons, where it mediates negative feedback suppression of thyroid-stimulating hormone (TSH) by triiodothyronine (T3). This isoform specificity is pharmacologically exploitable: selective TRbeta agonists such as resmetirom activate hepatic TRbeta1 to reduce lipogenesis and promote fatty acid oxidation while minimizing cardiac and bone effects mediated by TRalpha1. Unliganded TRs bind thyroid hormone response elements (TREs) in target gene promoters and recruit nuclear corepressors including NCoR1 (nuclear receptor corepressor 1) and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor), which recruit histone deacetylase (HDAC) complexes that maintain chromatin in a transcriptionally repressed state. Thyroxine (T4) or T3 binding induces a conformational change that releases corepressors and recruits coactivators, including SRC-1 (steroid receptor coactivator 1), activating transcription of target genes.8,9
Non-genomic thyroid hormone actions occur within seconds to minutes and do not require nuclear receptor binding or new protein synthesis. These include T3 activation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) signaling via a cytoplasmic pool of TRbeta1, T4 activation of integrin alphavbeta3 on the plasma membrane leading to mitogen-activated protein kinase (MAPK/ERK) signaling and angiogenesis, and direct modulation of ion channel conductances including the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that control cardiac pacemaker rate. These non-genomic effects contribute to the rapid cardiovascular responses seen in thyroid storm and likely to the rapid symptom improvement sometimes reported by patients converting from levothyroxine monotherapy to combination triiodothyronine/thyroxine (T3/T4) therapy.8,9
TRalpha1 dominates in heart, bone, and gut: excess at these sites produces AF, osteoporosis, and hyperdefecation; deficiency produces bradycardia, HF, and constipation. TRbeta1 dominates in liver: excess promotes fatty acid oxidation and reduced LDL cholesterol (the basis for resmetirom in MASH); deficiency produces hypercholesterolemia. TRbeta2 dominates in pituitary: this isoform drives TSH negative feedback. Knowing which TR isoform mediates which effect explains both the phenotype of thyroid dysfunction and the therapeutic rationale for selective TR agonism.
Levothyroxine sodium (synthetic L-thyroxine, T4) is the standard pharmacological preparation for thyroid hormone replacement and suppression therapy. Absorption occurs predominantly in the jejunum and upper ileum and is highly variable, with bioavailability ranging from 70% to 80% under ideal fasting conditions, falling substantially in the presence of food, gastric acid deficiency, intestinal malabsorption disorders, and co-administered medications. Standard tablet formulations are most affected by these variables; liquid levothyroxine solution and soft gelatin capsule formulations demonstrate improved and more consistent absorption because they do not require tablet dissolution and are less affected by intragastric pH. Levothyroxine should be taken on an empty stomach, 30–60 minutes before breakfast, or at bedtime at least 3 hours after the last meal, to maximize absorption. Patients who take levothyroxine with coffee, calcium supplements, or iron tablets consistently absorb less drug and require higher doses to maintain target thyroid-stimulating hormone (TSH) levels.10,11
Once absorbed, levothyroxine is extensively bound to plasma proteins: approximately 70% to thyroxine-binding globulin (TBG), 15% to transthyretin, also called thyroxine-binding prealbumin (TTR), and 10–15% to albumin. Only the unbound fraction (approximately 0.02% of total thyroxine, T4) is biologically active and available for cellular uptake and deiodination. TBG rises with estrogen, oral contraceptives, pregnancy, tamoxifen, and hepatitis, and falls with androgens, glucocorticoids, nephrotic syndrome, and severe liver disease. When TBG rises, total T4 rises to maintain the free fraction at physiological levels in a euthyroid state; when TBG falls, total T4 falls with the same TSH-confirmed euthyroid state. Free T4 measurement rather than total T4 is therefore required for accurate assessment in patients with altered TBG. The volume of distribution of levothyroxine is approximately 8–10 L/kg, and the elimination half-life is 6–7 days, allowing once-daily dosing with minimal peak-to-trough fluctuation.10,11
Approximately 80% of circulating triiodothyronine (T3) is derived from peripheral monodeiodination of T4 by type 1 deiodinase (D1) and type 2 deiodinase (D2); only 20% is secreted directly by the thyroid gland. Hepatic metabolism of T4 and T3 involves glucuronidation and sulfation, producing conjugates excreted in bile, with some enterohepatic recycling. Levothyroxine dosing is weight-based, with full replacement requiring approximately 1.6 mcg/kg/day in adults; elderly patients, those with residual thyroid function, and those with ischemic heart disease are initiated at lower doses (12.5–25 mcg/day) with gradual upward titration. Steady-state TSH should not be checked sooner than 6 weeks after any dose change, as the 6–7 day half-life requires four to five half-lives to reach a new equilibrium.10
Liothyronine (synthetic L-triiodothyronine, T3) has a bioavailability of approximately 95%, but a dramatically shorter elimination half-life of 1–2 days, producing marked peaks and troughs with conventional dosing. Liothyronine has 3–4 times the receptor affinity of T4 and produces more rapid onset of effect, making it useful in myxedema coma (IV liothyronine for rapid central nervous system reactivation) and in short-term thyroid hormone withdrawal protocols for thyroid cancer surveillance, where its shorter half-life permits earlier I-131 scanning than levothyroxine withdrawal would allow. The rationale for routine combination T4/T3 (levothyroxine plus liothyronine) therapy in hypothyroidism is debated: patients homozygous for the DIO2 (deiodinase iodothyronine type 2 gene) Thr92Ala variant may not generate sufficient intracellular T3 in brain tissue from T4 alone. Randomized controlled trials have produced inconsistent results, and the American Thyroid Association (ATA) guidelines do not recommend combination therapy as first-line treatment, though a trial may be considered in persistently symptomatic patients whose TSH is in the target range on adequate levothyroxine doses.7,11
Levothyroxine has a half-life of approximately 6–7 days. Reaching pharmacokinetic steady state requires four to five half-lives, which is 28–35 days. Checking TSH at 2 or 3 weeks after a dose change captures a non-equilibrium state that may not reflect the eventual steady-state TSH, leading to over-adjustment. Checking at 4–6 weeks ensures the measurement is made at or very near steady state. This same principle applies after any change in formulation, brand, or generic source, since bioavailability can differ by up to 12.5% between formulations even within the FDA-accepted bioequivalence window.
Drug interactions with levothyroxine fall into four mechanistic categories: impaired gastrointestinal absorption, accelerated hepatic metabolism, altered plasma protein binding, and direct induction of thyroid disease. Absorption interactions are the most common and most consistently overlooked in clinical practice. Calcium carbonate and calcium citrate reduce levothyroxine absorption by forming insoluble complexes with the hormone in the gastrointestinal lumen; ferrous sulfate and other iron salts bind levothyroxine through a similar complex-formation mechanism, reducing absorption by 30–40%. Aluminum-containing antacids, sucralfate, cholestyramine, colestipol, and sevelamer all bind levothyroxine in the gut lumen. Proton pump inhibitors (PPIs) reduce gastric acidity, increasing intraluminal pH and impairing dissolution of standard levothyroxine tablets, reducing absorption by 15–25% in susceptible patients; this interaction is largely avoided with liquid or soft-gel formulations. Patients requiring any of these agents should separate their levothyroxine dose by at least 4 hours.10,11
Hepatic enzyme inducers accelerate the glucuronidation and sulfation of thyroxine (T4) and triiodothyronine (T3), increasing their clearance and raising the levothyroxine dose requirement. Rifampin is the most potent inducer in clinical practice, activating pregnane X receptor (PXR) and upregulating CYP3A4 (cytochrome P450 3A4), UGT (uridine diphosphate-glucuronosyltransferase), and SULT (sulfotransferase) enzymes; patients starting rifampin for tuberculosis who are on stable levothyroxine will develop rising thyroid-stimulating hormone (TSH) within weeks and typically require dose increases of 20–50% or more. Phenytoin, carbamazepine, and phenobarbital induce thyroid hormone metabolism through similar PXR-mediated enzyme induction. Sertraline and other selective serotonin reuptake inhibitors (SSRIs) have been reported to increase levothyroxine requirements, possibly through induction of conjugating enzymes. Patients on stable levothyroxine who start any of these agents should have TSH rechecked at 6 weeks.10,12
Amiodarone, an iodine-rich antiarrhythmic agent containing approximately 37% iodine by weight, exerts multiple effects on thyroid hormone physiology and produces clinically significant thyroid disease in 15–20% of treated patients. Its mechanisms include: competitive inhibition of type 1 deiodinase (D1), reducing T4-to-T3 conversion and raising serum T4 while lowering T3; elevation of reverse T3 (rT3) through the same mechanism; transient Wolff-Chaikoff inhibition of new thyroid hormone synthesis in the first weeks of treatment; and direct thyroid cytotoxicity causing destructive thyroiditis. Amiodarone also displaces T4 from thyroxine-binding globulin (TBG) binding sites, transiently elevating free T4. The expected biochemical signature of amiodarone initiation within the first 3 months is: elevated free T4, reduced T3, elevated rT3, and TSH transiently up to 2–3 times the upper limit of normal; this pattern indicates normal drug effect, not thyroid disease. Persistent TSH elevation after 3 months indicates amiodarone-induced hypothyroidism; TSH suppression with elevated free T4 indicates amiodarone-induced thyrotoxicosis, requiring differentiation into type 1 (iodine excess-driven new synthesis, treated with thionamides plus perchlorate) and type 2 (destructive thyroiditis, treated with glucocorticoids).12,13
Immune checkpoint inhibitors (ICIs) including anti-PD-1 agents (pembrolizumab, nivolumab), anti-PD-L1 (programmed death-ligand 1) agents (atezolizumab, durvalumab), and anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) agents (ipilimumab) cause immune-related thyroid adverse events in 5–20% of patients depending on agent and combination. The most common pattern is painless thyroiditis with a transient hyperthyroid phase (2–6 weeks) followed by frequently permanent hypothyroidism. Tyrosine kinase inhibitors (TKIs) including sunitinib, sorafenib, and lenvatinib cause hypothyroidism through multiple mechanisms including type 3 deiodinase (D3) upregulation, reduced NIS (sodium-iodide symporter) expression, and direct thyroid vasculature damage; patients on long-term tyrosine kinase inhibitor therapy should have TSH monitored every 2–3 months. Lithium inhibits thyroglobulin (Tg) proteolysis and reduces T4 and T3 secretion from the thyroid follicle, causing clinical hypothyroidism in approximately 20–42% of long-term users and goiter through compensatory TSH-driven follicular hyperplasia.12,13
Within the first 3 months of amiodarone initiation, a mildly elevated free T4, reduced T3, elevated rT3, and TSH transiently up to 2–3x the upper reference limit are expected and do not indicate thyroid disease. After 3 months, a persistently elevated TSH indicates hypothyroidism requiring levothyroxine; a suppressed TSH with elevated free T4 requires urgent differentiation between type 1 and type 2 thyrotoxicosis. Amiodarone should not be discontinued without cardiology consultation, as abrupt withdrawal carries arrhythmia risk and the drug's 40–55 day half-life means thyroid effects persist for months regardless of discontinuation.
Ortiga-Carvalho TM, Chiamolera MI, Pazos-Moura CC, Wondisford FE. Hypothalamus-pituitary-thyroid axis. Compr Physiol. 2016;6(3):1387–1428.
doi:10.1002/cphy.c150027Feldt-Rasmussen U, Effraimidis G, Klose M. The hypothalamus-pituitary-thyroid (HPT) axis and its role in physiology and pathophysiology of other hypothalamus-pituitary functions. Mol Cell Endocrinol. 2021;525:111173.
doi:10.1016/j.mce.2021.111173Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002;87(3):1068–1072.
doi:10.1210/jcem.87.3.8165Portulano C, Paroder-Belenitsky M, Carrasco N. The Na+/I- symporter (NIS): mechanism and medical impact. Endocr Rev. 2014;35(1):106–149.
doi:10.1210/er.2012-1036Peeters RP, Visser TJ. Metabolism of thyroid hormone. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth, MA: MDText.com, Inc.; 2017. [Updated 2017 Jan 1]. Available at: www.ncbi.nlm.nih.gov/books/NBK285545/ (no DOI — online reference)
Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38–89.
doi:10.1210/edrv.23.1.0455Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751.
doi:10.1089/thy.2014.0028Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31(2):139–170.
doi:10.1210/er.2009-0007Flamant F, Gauthier K. Thyroid hormone receptors: the challenge of elucidating isotype-specific functions and cell-specific response. Biochim Biophys Acta. 2013;1830(7):3900–3907.
doi:10.1016/j.bbagen.2012.06.003Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200–1235.
doi:10.1089/thy.2012.0205Hennessey JV, Espaillat R. Diagnosis and management of subclinical hypothyroidism in elderly adults: a review of the literature. J Am Geriatr Soc. 2015;63(8):1663–1673.
doi:10.1111/jgs.13532Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
doi:10.1089/thy.2016.0229Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
doi:10.1089/thy.2015.0020